You are here

Ruxolitinib Shows Noteworthy Responses in Patients with Atypical CML

Atypical CML, or aCML is a form of CML where there is no expression of the BCR-Abl fusion gene. This has made it difficult to treat.

With the absence of a standard of care for chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML), 2 rare BCR-ABL1-negative myeloid neoplasms, ruxolitinib (Jakafi) may be a viable treatment option after a phase II study (NCT02092324) showed potential for response in this patient population.